David M. Ellison

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

The blockade of Fc receptor-mediated clearance of immune complexes <i>in vivo</i> by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes.

RJ Kurlander, David M. Ellison, J Hall · The Journal of Immunology · 1984 · 118 citations

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

Mark M. Awad, Q.S-C. Chu, Leena Gandhi et al. · Lung Cancer · 2016 · 62 citations

Bi 2536, Medicine, Pathology +9

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher et al. · npj Breast Cancer · 2021 · 13 citations · Full text

Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.

Guilherme Rabinowits, Soo Jung Park, David M. Ellison et al. · Journal of Clinical Oncology · 2021 · 12 citations

Checkpoint Inhibition, Cemiplimab 350, Immunodeficiencies +26